Abstract
Multiplex assays represent a new paradigm for diagnostics. The simultaneous measure of multiple analytes from a single sample is advantageous in creating disease-associated panels that enable more accurate prognosis or diagnosis of the disease state. Furthermore, multiplexing may reduce reagent consumption, sample requirements and labor thereby lowering the cost per test. Here we describe a novel multiplex immunoassay technology based upon creating microarrays in microtiter plates that are formed upon the self-assembly of oligonucleotide–antibody conjugates.